Cel-Sci Corp (CVM) Stock Price, Quote & News

Company Profile

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development to treat cancer and other diseases by using the immune system in the United States. The company's lead immunotherapy is Multikine, which has completed Phase III clinical trials for the potential treatment of certain head and neck cancers. It is also developing Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune syste...

Industry: Biotechnology

Sector: Healthcare

Phone: 703 506 9460

Website: cel-sci.com

Address:

8229 Boone Boulevard, Suite 802, Vienna, United States

DeepThought Apr. 19 at 5:18 AM

$CVM Everything is coming together!

0 · Reply

DeepThought Apr. 19 at 5:15 AM

$CVM

0 · Reply

BioGLovesMe Apr. 19 at 5:13 AM

$CVM There is nothing bullish about this dilution. There haven't been any updates regarding the Saudi farce, no updates about when the "confirmatory trial" might start, and no independent confirmation from either First Berlin or Dallah that they are involved in this turd. Oh and the P3 trial failed all of its endpoints necessitating the datamining of the new "target population" Geert has only so far been successful in getting the FDA to approve a trial redo with. You are an absolute fool if you think things are going anywhere near well. Geert will happily take your money to add to his stroopwafel retirement fund.

0 · Reply

DeepThought Apr. 19 at 5:11 AM

$CVM Don't forget! - If Multikine had truly failed, the FDA would never have approved a confirmatory study. Regulators don’t validate dead drugs. - CVM didn’t chase the Saudis — the SFDA invited them to file for BMD, which tells you exactly who wanted this partnership!

0 · Reply

Isitreallyhim Apr. 19 at 1:00 AM

$CVM look at the SP. 30 percent dilution and it’s barely moved 8%. Hmmmm

1 · Reply

Isitreallyhim Apr. 19 at 12:55 AM

$CVM fits. Statement concerning future with SFDA is an absolute tell that something is in the works. And we wait

1 · Reply

ImmxBeliever Apr. 18 at 6:52 PM

$CVM Never forget Trial failed https://www.fiercebiotech.com/biotech/cel-sci-cancer-phase-3-misses-primary-endpoint-sinking-stock

0 · Reply

ImmxBeliever Apr. 18 at 4:44 PM

$CVM everything gerd does is great Copioum

0 · Reply

DeepThought Apr. 18 at 12:24 PM

$CVM -> An investment restriction for EU and Middle Eastern investors is currently in place. -> This restriction is lifted immediately upon SFDA approval.

0 · Reply

SemiRetiredEngineer Apr. 18 at 1:13 AM

$CVM Pretty much on the cash timeline expected - they are very low on cash right now, I will be surprised if they get $4.36 per share - as "assumed" in the S-1. If they are able to hold a price in this neighborhood, then it is likely an aligned buyer - and that buyer must know something to want to do this - which raises some insider trading questions. If they can't, well, it means the SFDA thing is in trouble (at least as far as any kind of accelerated track like BTM in concerned). NO news has been released whatsoever. They had ~8.5M shares out already (I believe, but haven't looked in a while) - this adds ~3.5M so if you're long your ownership in the company will be - assuming they can sell this many shares - about 70% of what is was. It was also obvious that this was being pumped - on very low volume. $15M is only enough to start the confirmatory trial for FDA and keep the lights on for a finite period. We shall see.....

3 · Reply

CEL-SCI Reports Fiscal First Quarter 2026 Results

Dec 29, 2025, 9:00 AM EST - 3 months ago

CEL-SCI Reports Fiscal 2025 Results

Oct 20, 2025, 9:00 AM EDT - 6 months ago

CEL-SCI Presentation at LD Micro "Main Event" Available on Tuesday, October 21, 2025

Oct 10, 2025, 8:00 AM EDT - 6 months ago

CEL-SCI Corporation to Present at LD Micro "Main Event" Investor Conference

Aug 29, 2025, 12:52 PM EDT - 8 months ago

CEL-SCI Announces Closing of $10 Million Public Offering

Aug 27, 2025, 10:35 PM EDT - 8 months ago

CEL-SCI Announces Pricing of $10 Million Public Offering

Aug 27, 2025, 5:25 PM EDT - 8 months ago

CEL-SCI Announces Proposed Public Offering

Aug 14, 2025, 10:45 AM EDT - 8 months ago

CEL-SCI Reports Fiscal Third Quarter 2025 Financial Results

Aug 13, 2025, 9:15 AM EDT - 8 months ago

CEL-SCI's Multikine Head and Neck Cancer Immunotherapy Breakthrough Medicine Designation Filed in Saudi Arabia: Allows for Patient Access and Reimbursement/Sale Upon Granting of the Designation Which Takes Approximately 60 Days Based on SFDA Timeline

Jul 14, 2025, 4:05 PM EDT - 9 months ago

CEL-SCI Announces Closing of $5.7 Million Offering Priced At-The-Market Under NYSE American Rules

Jul 11, 2025, 12:16 PM EDT - 10 months ago

CEL-SCI Announces Pricing of $5.7 Million Offering Priced At-the-Market Under NYSE American Rules

Jul 11, 2025, 9:15 AM EDT - 10 months ago

CEL-SCI to Sign Partnership Agreement With Leading Saudi Arabian Pharma Company for Multikine in the Treatment of Head & Neck Cancer

Jun 18, 2025, 9:00 AM EDT - 10 months ago

FDA's Approval of Keytruda for PD-L1 Positive Head and Neck Cancer Patients Signals a Clear Pathway for CEL-SCI's Multikine to Address a Major Unmet Need in PD-L1 Negative Cancer Patients

May 23, 2025, 4:05 PM EDT - 11 months ago

CEL-SCI Announces Closing of Public Offering

May 21, 2025, 8:14 PM EDT - 11 months ago

CEL-SCI Announces Pricing of Public Offering

May 21, 2025, 8:00 AM EDT - 11 months ago

CEL-SCI's Multikine Investigational Cancer Medicine Potentially Available for Commercialization by Summer 2025 in Saudi Arabia

May 19, 2025, 2:40 PM EDT - 11 months ago

CEL-SCI Announces Combination of Common Stock

May 15, 2025, 9:00 AM EDT - 1 year ago

CEL-SCI Reports Fiscal Second Quarter 2025 Financial Results

Apr 23, 2025, 8:30 AM EDT - 1 year ago

CEL-SCI to File for Regulatory Approval of Multikine in Saudi Arabia—Pursuing Local Partnerships for Commercialization and Manufacturing to Serve Middle East and North Africa Market

Apr 8, 2025, 9:51 AM EDT - 1 year ago

New Study in the Scientific Journal “Cancer Cell” Supports CEL-SCI's Strategy to Seek Early Approval for Multikine in Head and Neck Cancer Based on Pre-Surgical Tumor Responses

Mar 24, 2025, 9:00 AM EDT - 1 year ago

CEL-SCI Reports New Data: Treatment with Multikine Resulted in up to 95% Improvement in Quality of Life for Head and Neck Cancer Patients

Mar 18, 2025, 4:05 PM EDT - 1 year ago

CEL-SCI Announces Closing of $2.5 Million Offering

Mar 17, 2025, 3:24 PM EDT - 1 year ago

CEL-SCI Announces Pricing of $2.5 Million Offering

Mar 17, 2025, 8:00 AM EDT - 1 year ago

CEL-SCI's Head and Neck Cancer Registration Study Protocol Clears FDA Review—in Talks with Potential Partners Interested in Commercialization of Multikine

Mar 14, 2025, 8:30 AM EDT - 1 year ago

Journal of the American Medical Association (JAMA) Study Provides Further Evidence that CEL-SCI's Multikine Can Treat Unmet Need in ~70% of Head and Neck Patients Based on PD-L1 Expression

Feb 20, 2025, 8:00 AM EST - 1 year ago

CEL-SCI to Initiate Multikine Confirmatory Phase 3 Cancer Trial

Feb 18, 2025, 8:30 AM EST - 1 year ago

CEL-SCI Reports Fiscal Q1 2025 Financial Results: Multikine Shows Pre-Surgical Tumor Elimination and Regression in Just 3 Weeks

Jan 14, 2025, 9:00 AM EST - 1 year ago

CEL-SCI Reports Fiscal 2024 Results: Set to Commence Confirmatory Study That Could Bring New Standard of Care to Head & Neck Cancer

Dec 31, 2024, 4:05 PM EST - 1 year ago

CEL-SCI Announces Closing of $5 Million Offering

Dec 29, 2024, 8:41 PM EST - 1 year ago

CEL-SCI Announces Pricing of $5 Million Public Offering

Dec 27, 2024, 5:05 PM EST - 1 year ago

CEL-SCI Announces Proposed Public Offering of Common Stock

Dec 12, 2024, 9:15 AM EST - 1 year ago

CEL-SCI Highlights Biological Rationale for the Use of Multikine in the Confirmatory Registration Head and Neck Cancer Study

Nov 7, 2024, 8:15 AM EST - 1 year ago

U.S. FDA and CEL-SCI Agree on Use of PD-L1 Biomarker to Select Head and Neck Cancer Patients for Marketing Registration Study to Commence Q1 2025

Oct 22, 2024, 9:15 AM EDT - 1 year ago

FDA's Oncologic Drugs Advisory Committee Decision on Checkpoint Inhibitors Substantiates Potential of CEL-SCI's Multikine® to Address Major Treatment Gap for PD-L1 Negative Cancer Patients

Oct 1, 2024, 6:00 AM EDT - 1 year ago

CEL-SCI Selects Ergomed as CRO as it Gears Up for Confirmatory FDA Registration Study of Multikine® in Head and Neck Cancer

Sep 16, 2024, 7:30 AM EDT - 1 year ago

CEL-SCI's Multikine® Increased 5-Year Survival Rate to 82.6% in Locally Advanced Resectable Head & Neck Cancer Patients Who Were Deemed to be in the Treatment Group for Surgery and Radiation

Sep 10, 2024, 9:32 AM EDT - 1 year ago

CEL-SCI to Present New Data for Multikine® Head & Neck Cancer Immunotherapy at the European Society for Medical Oncology 2024 Congress

Sep 4, 2024, 9:00 AM EDT - 1 year ago

The UK's Medicines & Healthcare Products Regulatory Agency Grants CEL-SCI a Pediatric Waiver, Bringing Multikine® One Step Closer to Future Marketing Clearance

Aug 15, 2024, 8:00 AM EDT - 1 year ago

CEL-SCI Corporation Reports Third Quarter Fiscal 2024 Financial Results

Jul 29, 2024, 4:05 PM EDT - 1 year ago

CEL-SCI Announces Closing of $10.8 Million Offering

Jul 26, 2024, 11:52 AM EDT - 1 year ago

CEL-SCI Announces Pricing of $10.8 Million Offering

Jul 26, 2024, 8:23 AM EDT - 1 year ago

CEL-SCI's Phase 3 Population Analysis for Upcoming Confirmatory Registration Study in Head & Neck Cancer Demonstrates Well Balanced Patient Population, Confidence in Clinical Results

Jul 8, 2024, 9:15 AM EDT - 1 year ago

CEL-SCI Appoints Robert Watson as Chairperson of the Board

Jun 18, 2024, 8:00 AM EDT - 1 year ago

CEL-SCI Presents Head & Neck Cancer Data at Iddst Annual Congress in Budapest: Risk of Death Cut in Half for Patients Treated With Multikine in the Target Population

Jun 6, 2024, 7:00 AM EDT - 2 years ago

Dr. Giovanni Selvaggi, Who Has Brought Several Oncology Drugs to Market, Joins CEL-SCI as Clinical Advisor

May 16, 2024, 9:00 AM EDT - 2 years ago

CEL-SCI Corporation Reports Second Quarter Fiscal 2024 Financial Results

May 8, 2024, 9:00 AM EDT - 2 years ago

CEL-SCI Receives FDA Go-Ahead for Its Confirmatory Study of Multikine in the Treatment of Head & Neck Cancer

Apr 23, 2024, 9:00 AM EDT - 2 years ago

CEL-SCI Appoints Mario Gobbo to Its Board of Directors

Apr 16, 2024, 9:00 AM EDT - 2 years ago

Channel V Media Expands Content Marketing Division; Names Gabriella Bock Director of Content

Mar 19, 2024, 9:00 AM EDT - 2 years ago

CEL-SCI's LEAPS Vaccine Offers Promising New Paradigm to Treat Rheumatoid Arthritis: Published in Frontiers in Immunology

DeepThought Apr. 19 at 5:18 AM

$CVM Everything is coming together!

0 · Reply

DeepThought Apr. 19 at 5:15 AM

$CVM

0 · Reply

BioGLovesMe Apr. 19 at 5:13 AM

0 · Reply

DeepThought Apr. 19 at 5:11 AM

0 · Reply

Isitreallyhim Apr. 19 at 1:00 AM

$CVM look at the SP. 30 percent dilution and it’s barely moved 8%. Hmmmm

1 · Reply

Isitreallyhim Apr. 19 at 12:55 AM

$CVM fits. Statement concerning future with SFDA is an absolute tell that something is in the works. And we wait

1 · Reply

ImmxBeliever Apr. 18 at 6:52 PM

$CVM Never forget Trial failed https://www.fiercebiotech.com/biotech/cel-sci-cancer-phase-3-misses-primary-endpoint-sinking-stock

0 · Reply

ImmxBeliever Apr. 18 at 4:44 PM

$CVM everything gerd does is great Copioum

0 · Reply

DeepThought Apr. 18 at 12:24 PM

$CVM -> An investment restriction for EU and Middle Eastern investors is currently in place. -> This restriction is lifted immediately upon SFDA approval.

0 · Reply

SemiRetiredEngineer Apr. 18 at 1:13 AM

3 · Reply

DeepThought Apr. 18 at 12:57 AM

$CVM Where your IMMX story ends, CVM is only getting started. Could CVM give a firm approval date? No. That’s exactly why there was no famous ‘Letter to Shareholders’ afterwards. Just like FDA, MHRA and the rest, they’re not allowed to make any positive, non‑neutral noise before a decision. Approval can drop on a Sunday or next week. And when it does, GK will be kicking himself — but that’s life!

0 · Reply

ImmxBeliever Apr. 18 at 12:36 AM

$CVM copium

1 · Reply

DeepThought Apr. 17 at 11:38 PM

$CVM Any investment by European or Middle Eastern investors in restricted CEL-SCIstock after SFDA approval of the breakthrough designation shall not be covered by this prohibition. After the offering, there will be 12,000,000 shares outstanding and about $15,000,000 in cash by the end of the year. That is perfectly fine. 1,000 patients, $200,000 revenue per patient, a revenue multiple of 30, and 12 million shares outstanding. - > The fair value is still well above $50

0 · Reply

BioGLovesMe Apr. 17 at 11:00 PM

$CVM @Thebullrun @IChiGOdoranZ @SmallCapGrowth any commemts from our favorite paid pumper? Did ThinkEquity give you prior knowledge of this?

0 · Reply

BioGLovesMe Apr. 17 at 10:57 PM

$CVM BTW only one brief mention of the Saudi farce: "We have completed our Breakthrough Medicine Designation application for Multikine and submitted it to the SFDA." No mentions of the 30 working day decision timeframe which has now gone over 5 times that long, nor are Dallah and First Berlin even mentioned in the entire S-1. What happened to partnership being finalized in Q3/2025? Why hasn't the "confirmatory trial" started? Why are they only raising $13M when the "confirmatory trial" was quoted by Geert as having a cost of $30M? 1-800-Gambler

0 · Reply

BioGLovesMe Apr. 17 at 10:42 PM

$CVM Welp.....those of us on the right side of this trade were saying this would happen. The geriatric will need to update us on his new average....and Kev is on SW in the Bagholder Sanitarium. Happy permabagholding!

0 · Reply

ImmxBeliever Apr. 17 at 10:28 PM

$CVM http://archive.fast-edgar.com/20260417/A8BZP22CZ222NTZ5222G2ZZGA8MAZS22ZV82

0 · Reply

Johnyd Apr. 17 at 10:27 PM

$CVM JAYSUS CREEST! so obvious! the delusion of crowds?

1 · Reply

ImmxBeliever Apr. 17 at 10:20 PM

$CVM $1.69 per share This is toast

0 · Reply

Johnyd Apr. 17 at 10:13 PM

$CVM call gavin yet? LOL!

0 · Reply

ImmxBeliever Apr. 17 at 10:07 PM

$CVM serious question for bulls: If the Saudi / SFDA deal is really right around the corner… why are they filing an S-1 with: • “going concern” language • ~$13M raise • heavy dilution • best-efforts structure (no guaranteed demand) You don’t do a dilutive survival raise right before a revenue-generating deal. If Saudi were: - imminent - credible - bringing in cash 👉 this raise would be smaller, structured, or not needed at all. Instead, management is telling you (without saying it): they need cash now — not later Saudi might be a story. This filing is reality. Follow the money, not the narrative.

0 · Reply

ImmxBeliever Apr. 17 at 10:03 PM

$CVM hi john When plan b Show me where daddy touched you on this doll Woof

0 · Reply

Market Cap	41.87M
Revenue (ttm)	0.00
Net Income (ttm)	-25.41M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	53,300
Avg Vol	43,124
Day's Range	N/A - N/A
Shares Out	8.46M
Stochastic %K	100%
Beta	0.99
Analysts	Strong Sell
Price Target	$180.18